Natixis lowered its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) by 0.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 133,678 shares of the company’s stock after selling 403 shares during the quarter. Natixis owned approximately 0.09% of Ionis Pharmaceuticals worth $5,046,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Edgestream Partners L.P. bought a new stake in shares of Ionis Pharmaceuticals in the 4th quarter valued at approximately $1,035,000. Tower Research Capital LLC TRC increased its stake in shares of Ionis Pharmaceuticals by 722.0% during the 3rd quarter. Tower Research Capital LLC TRC now owns 11,755 shares of the company’s stock worth $520,000 after purchasing an additional 10,325 shares during the last quarter. Gateway Investment Advisers LLC raised its holdings in shares of Ionis Pharmaceuticals by 1.9% during the 4th quarter. Gateway Investment Advisers LLC now owns 51,174 shares of the company’s stock valued at $1,933,000 after purchasing an additional 975 shares in the last quarter. Vanguard Personalized Indexing Management LLC lifted its stake in shares of Ionis Pharmaceuticals by 18.2% in the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 6,159 shares of the company’s stock valued at $233,000 after purchasing an additional 950 shares during the last quarter. Finally, Seven Eight Capital LP boosted its holdings in Ionis Pharmaceuticals by 13.2% in the fourth quarter. Seven Eight Capital LP now owns 5,990 shares of the company’s stock worth $226,000 after purchasing an additional 700 shares in the last quarter. 87.32% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of analysts have weighed in on the company. Morgan Stanley boosted their price target on Ionis Pharmaceuticals from $40.00 to $42.00 and gave the stock an “equal weight” rating in a research report on Tuesday, April 11th. Sanford C. Bernstein assumed coverage on Ionis Pharmaceuticals in a report on Tuesday, March 21st. They set an “underperform” rating and a $31.00 price target on the stock. SVB Leerink dropped their price target on shares of Ionis Pharmaceuticals from $34.00 to $27.00 and set a “market perform” rating on the stock in a research report on Thursday, February 23rd. Needham & Company LLC reaffirmed a “buy” rating and set a $60.00 price objective on shares of Ionis Pharmaceuticals in a report on Thursday, February 23rd. Finally, Citigroup upgraded shares of Ionis Pharmaceuticals from a “sell” rating to a “neutral” rating and lifted their target price for the stock from $30.00 to $36.00 in a report on Thursday, May 4th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Ionis Pharmaceuticals has an average rating of “Hold” and a consensus target price of $46.64.
Ionis Pharmaceuticals Stock Performance
Ionis Pharmaceuticals (NASDAQ:IONS – Get Rating) last issued its quarterly earnings results on Wednesday, May 3rd. The company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.13. Ionis Pharmaceuticals had a negative return on equity of 57.58% and a negative net margin of 56.85%. The firm had revenue of $131.00 million for the quarter, compared to analyst estimates of $126.88 million. During the same period in the previous year, the company posted ($0.46) earnings per share. The company’s quarterly revenue was down 7.7% compared to the same quarter last year. Equities research analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.54 earnings per share for the current year.
Insider Activity at Ionis Pharmaceuticals
In related news, CEO Brett P. Monia sold 4,931 shares of the stock in a transaction dated Monday, May 22nd. The shares were sold at an average price of $40.14, for a total value of $197,930.34. Following the completion of the transaction, the chief executive officer now owns 140,374 shares of the company’s stock, valued at $5,634,612.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Brett P. Monia sold 4,931 shares of the stock in a transaction that occurred on Monday, May 22nd. The stock was sold at an average price of $40.14, for a total value of $197,930.34. Following the completion of the transaction, the chief executive officer now directly owns 140,374 shares of the company’s stock, valued at approximately $5,634,612.36. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Patrick R. O’neil sold 1,527 shares of the business’s stock in a transaction on Wednesday, May 24th. The shares were sold at an average price of $41.70, for a total value of $63,675.90. Following the completion of the sale, the executive vice president now directly owns 40,355 shares in the company, valued at approximately $1,682,803.50. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 7,130 shares of company stock worth $286,134. 2.36% of the stock is owned by corporate insiders.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T.
Read More
- Get a free copy of the StockNews.com research report on Ionis Pharmaceuticals (IONS)
- Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition
- Tax Software Specialist Vertex In Buy Zone After Base Breakout
- What is a Mutual Fund? How Does it Work?
- How to Choose a Brokerage Account or Online Broker
- BJ’s Restaurants’ Approaching Buy Point As Earnings Surge 150%
Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating).
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
